Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transthyretin (TTR)-Mediated Amyloidosis”

Showing 20 of 0 results

Not applicableLooking for participantsNCT06465810
What this trial is testing

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Who this might be right for
Transthyretin AmyloidosisATTR-CMATTRv-PN+3 more
AstraZeneca 1,850
Testing effectiveness (Phase 2)Study completedNCT02292186
What this trial is testing

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 25
Not applicableActive Not RecruitingNCT05873868
What this trial is testing

Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran

Who this might be right for
Transthyretin AmyloidosisAmyloidosis, Hereditary
Rennes University Hospital 20
Large-scale testing (Phase 3)WithdrawnNCT04882735
What this trial is testing

Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

Who this might be right for
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Eidos Therapeutics, a BridgeBio company
Post-approval studies (Phase 4)Ended earlyNCT04306510
What this trial is testing

Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN

Who this might be right for
Hereditary Transthyretin Amyloidosis With Polyneuropthy
Akcea Therapeutics 8
Large-scale testing (Phase 3)Study completedNCT04136171
What this trial is testing

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Who this might be right for
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals, Inc. 1,438
Not applicableNo Longer AvailableNCT05505838
What this trial is testing

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

Who this might be right for
Transthyretin-mediated Amyloidosis With CardiomyopathyATTR Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Early research (Phase 1)Study completedNCT02797847
What this trial is testing

A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

Who this might be right for
Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)
Alnylam Pharmaceuticals 80
Testing effectiveness (Phase 2)Study completedNCT01961921
What this trial is testing

The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 27
Large-scale testing (Phase 3)WithdrawnNCT04418024
What this trial is testing

Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

Who this might be right for
Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy
Eidos Therapeutics, a BridgeBio company
Testing effectiveness (Phase 2)Study completedNCT01981837
What this trial is testing

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 26
Early research (Phase 1)Study completedNCT05661916
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

Who this might be right for
Transthyretin-Mediated Amyloidosis
Alnylam Pharmaceuticals 96
Testing effectiveness (Phase 2)Study completedNCT01617967
What this trial is testing

Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis

Who this might be right for
TTR-mediated Amyloidosis
Alnylam Pharmaceuticals 29
Testing effectiveness (Phase 2)Active Not RecruitingNCT07608354
What this trial is testing

Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

Who this might be right for
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
AstraZeneca 326
Large-scale testing (Phase 3)Looking for participantsNCT06128629
What this trial is testing

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Who this might be right for
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intellia Therapeutics 1,200
Not applicableApproved For MarketingNCT02939820
What this trial is testing

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

Who this might be right for
TTR-mediated AmyloidosisAmyloidosis, HereditaryAmyloid Neuropathies, Familial+3 more
Alnylam Pharmaceuticals
Large-scale testing (Phase 3)Study completedNCT03862807
What this trial is testing

Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

Who this might be right for
Amyloidosis, FamilialTransthyretin Amyloidosis
Alnylam Pharmaceuticals 24
Large-scale testing (Phase 3)Study completedNCT04136184
What this trial is testing

NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Who this might be right for
Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Ionis Pharmaceuticals, Inc. 168
Not applicableStudy completedNCT06073574
What this trial is testing

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

Who this might be right for
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Ionis Pharmaceuticals, Inc. 160
Large-scale testing (Phase 3)Study completedNCT02510261
What this trial is testing

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Who this might be right for
Amyloidosis
Alnylam Pharmaceuticals 211
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation